Highlights Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
0.76 ^USD	0.00%		-3.80%	-14.51%

Apr. 05	Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	MT
Apr. 05	Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ADRs Close Lower; Moatable Inc. Declines 33.3%	Apr. 04	DJ
Syncona notes investee Achilles's annual loss narrows	Apr. 04	AN
Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 04	CI
Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	Apr. 04	CI
Syncona notes investee company's quarterly loss	Nov. 14	AN
Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Syncona's portfolio Achilles Therapeutics net loss narrows	23-08-04	AN
Achilles Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Syncona say portfolio clinical company Achilles have widened losses	23-05-10	AN
Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Achilles Therapeutics plc Announces New Immunogenicity Prediction Application of its AI-Powered PELEUS Platform Uniquely Identifies Most Potent T Cell Antigens	23-05-10	CI
Achilles Therapeutics : Corporate Presentation – March 2023	23-03-07	PU
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-07	CI
Achilles Therapeutics : Corporate Presentation – January 2023	23-01-05	PU
Syncona's Achilles says cancer treatment shows promise; seals buy	22-12-01	AN
Achilles Therapeutics plc Updates Interim Results from the Ongoing Phase I/IIa Chiron and Thetis Clinical Trials	22-11-30	CI
Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Achilles Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Achilles Therapeutics plc

Equities

ACHL

US00449L1026

Highlights

Filters